{"id":"NCT00641745","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia","officialTitle":"Long-Term Safety, Tolerability, and Effectiveness of Lurasidone in Subjects With Schizophrenia or Schizoaffective Disorder: A Randomized, Active Comparator-Controlled Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2010-07","completion":"2010-07","firstPosted":"2008-03-24","resultsPosted":"2011-10-06","lastUpdate":"2015-06-22"},"enrollment":629,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia","Schizoaffective Disorder"],"interventions":[{"type":"DRUG","name":"Lurasidone HCl","otherNames":[]},{"type":"DRUG","name":"Risperidone","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is safe and tolerable long term among clinically stable patients. The study will also assess the long term effectiveness of lurasidone as compared to an active comparator.","primaryOutcome":{"measure":"Number of Participants With Adverse Events.","timeFrame":"12 months","effectByArm":[{"arm":"Lurasidone","deltaMin":395,"sd":null},{"arm":"Risperidone","deltaMin":189,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":4},"locations":{"siteCount":73,"countries":["United States","Argentina","Brazil","Chile","Croatia","Israel","South Africa","Thailand"]},"refs":{"pmids":["21075600","22395527","33098548","32370778","28433500"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":46,"n":419},"commonTop":["Somnolence","Insomnia","Nausea","Sedation","Weight Increased"]}}